We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New COVID-19 Test Shows Patients with Suppressed Immune Systems Can Also Achieve Good Immune Response to SARS-CoV-2

By LabMedica International staff writers
Posted on 31 Aug 2020
A new test that provides information on the immune response to the novel coronavirus in patients who need to take immunosuppressive drugs has shown that these patients can achieve a good immune response to SARS-CoV-2 despite immunosuppression.

A research team from the University Hospital at Ruhr-Universität Bochum (RUB Bochum, Germany) has developed the test which can be used to adapt immunosuppressive therapy individually during a COVID-19 infection, such as following an organ transplantation. More...
The test is of great clinical relevance for transplant patients as it provides information that goes far beyond a pure antibody test.

Transplant patients are affected in several ways: in addition to the chronic illness that led to organ failure and subsequent transplantation, transplant patients need to take medications that suppress the defenses of their own immune system. Chronically ill patients with impaired immune defenses have an increased risk of suffering from a severe COVID-19 infection. It was previously unknown whether patients could develop a sufficient reaction against the new coronavirus under the influence of immunosuppressive drugs.

With the help of the test, the team demonstrated that transplant patients are very capable of achieving a good immune response despite immunosuppression. In addition to high antibody titres, large quantities of T lymphocytes, which are responsible for killing infected cells, were found in the current case study.

“Until now, it has not been known whether our transplant patients are capable of forming a sufficient immune response to the new coronavirus,” said Professor Timm Westhoff, Director of Medical Clinic I at Marien Hospital Herne, who led the team of researchers. “The data obtained help us to deal with immunosuppression during the current pandemic. The test allows us to individually adjust immunosuppression when a patient is suffering from COVID-19.”

Related Links:
Ruhr-Universität Bochum


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.